The magazine for alumni and friends of the UB School of Management
Issue link: http://ubschoolofmanagement.uberflip.com/i/1543053
"At Cure, our strength is our team," he says. "We have expertise across disease areas and modality. I match my legal and financial skills with scientists who are smarter than me — and that's the secret." For Fallace and his team, artificial intelligence is another tool in their arsenal that will help them rapidly identify and assess high-potential science. "We use AI as a toolset to write code and access data- sets more efficiently," he says. "We've developed a system called Mendel, a genetics data warehouse that supports faster, smarter decision-making." When science becomes care Bringing therapies from lab to patient is shaped by economics, policy and infrastructure. Aer the science, strategy and investment are in place, innovation is tested in the health care system where the patient feels the impact of a decade or more of research. Milind Sohoni, chair and professor of operations manage- ment and strategy, and faculty director of the Center for Supply Chain Analytics, conducts research in such areas as supply chain and health care analytics. "The real question is how to reach communities and bring everyone into the health care fold," Sohoni says. "The COVID-19 pandemic offers examples of how to innovate to build the capabilities of even getting vaccines to very remote areas through temperature-controlled transport. Over the last decade, we've seen several innovations in remote medicine, monitoring and pharmaceutical supply chains to make health care more affordable and accessible." The most powerful breakthrough in biotech, then, may not be a pharmaceutical or biological. It may be ensuring the solution reaches patients who need it most. And, School of Management alumni like Borgeson and his team at Kodiak Sciences, who are creating medicines to prevent vision loss, lean into the challenge. "There is no business, in my opinion, that is more complex than a fully integrated pharmaceutical company that does early-stage research, manufacturing, clinical trials and commercialization, all under stringent regu- latory oversight. Each of these disciplines is deep with complexity," Borgeson says. "There is a lot to dig into. It is incredibly rewarding. And, at the end of the day, you're benefiting people by delivering important medicines that improve the quality of lives." "AI can reshape biomedical research. We are building and training an efficient AI model to process more than 40,000 academic papers related to this specific topic to help scientists identify patterns and zero in on the most relevant research," says Namratha Pulluru, MS '24, and management PhD candidate funded by the project. "The AI functions like an additional scientist on the team that you can ask a question of and it will analyze data and generate predictions that the scientists test and validate in the lab." By participating in projects like these that combine experimental and computational approaches, management students can impact fields they may never have imagined. Dominic Sellitto and Edward Snell in a lab at the UB Hauptman-Woodward Research Institute. Pulluru Spring 2026 Buffalo Business 13 Sohoni